. Lung cancer kills approximately 160,000 people in the US annually, making it the deadliest type of cancer, with a 5-year survival rate of only 15.9% of diagnosed cases. As a chaperone protein, heat shock protein 90 (HSP90) is essential to support activity of many proteins involved in oncogenesis, and its overexpression correlates with worse outcomes. Although early HSP90 inhibitors were not clinically successful due to toxic side effects, second-generation compounds, such as ganetespib, are showing considerable promise in late stage clinical trials, including some for lung cancer. Following extensive preliminary short interfering (si)RNA screening, I found that depletion of anti-Mllerian hormone (AMH) and the AMH type II receptor (AMHRII) significantly sensitized three KRAS-mutated lung cancer cell lines to ganetespib. Importantly, AMH is a member of the transforming growth factor (TGF)-? superfamily and relates to TGF-? signaling by sharing parts of an effector cascade. TGF-? signaling is frequently involved in lung cancer proliferation, survival and metastasis, the last being the deadliest aspect of this malignancy. TGF-? has been studied extensively, but aspects of its function in aggressive cancer remain opaque. Our preliminary data suggests a novel autocrine-signaling loop involving AMH and AMHRII, representing the first time these proteins have been identified as functioning in a non-gonadal tissue cancer context. Intriguingly, Taipale et al. recently discovered that AMHRII stability is most dependent on HSP90 out of 314 tested kinases, while online databases and my own investigations have established significant expression of AMH and AMHRII in a subset of lung cancer cell lines as well as in many primary lung cancers. Thus, we propose that AMH and AMHRII play a critical role in a subpopulation of lung cancers, and may be exploitable targets to potentiate the efficacy of current and novel therapies or at minimum be utilized as biomarkers. Our broad, long-term objectives are to further elucidate the role TGF-? plays in cancer proliferation and metastasis and how this information can be used to improve the status quo of patients afflicted with lung cancer. Our three aims will better delineate AMH as a pro-survival ligand linked to TGF-? signaling and explore the translational possibilities of our findings. For our first aim, we will use siRNA and overexpression experiments to probe interactions of AMH and the TGF-? effector cascades and explore links of AMH to epithelial-mesenchymal transition.
The second aim will use in vitro testing of combinations of ganetespib with AMHIIR-targeting antibodies or an AMH-targeting fusion protein, in the context of altered AMH function, and xenograft mouse models will be used to study the effects of short hairpin RNA (shRNA) knockdown of AMH in combination with ganetespib treatment in vivo. Lastly, we will stain tissue microarrays of human lung cancer for AMH, AMHRII, HSP90 and several other proteins as part of a preclinical assessment.

Public Health Relevance

We propose to investigate a novel aspect of a well-established driving mechanism of lung cancer, which is the deadliest cancer in the US. This work focuses on two proteins, AMH and AMHRII, which are appreciated to function in development of the male and female reproductive system, but which we have for the first time shown to have action in drug resistance in lung cancer. Our work will investigate the function of this, in the case of lung cancer, completely novel set of signaling proteins, and use this information to guide evaluation of therapeutic approaches, with the goal of informing the clinical management of a subset of lung cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Drexel University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Beck, Tim N; Young, Natalee G; Erickson, Michelle L et al. (2017) Rare antibody-associated hemolytic transfusion reaction and transfusion-related acute lung injury: a case report. BMC Surg 17:48
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Gaponova, Anna V; Deneka, Alexander Y; Beck, Tim N et al. (2017) Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Oncotarget 8:19156-19171
Beck, Tim N; Golemis, Erica A (2016) Genomic insights into head and neck cancer. Cancers Head Neck 1:
Kudinov, Alexander E; Deneka, Alexander; Nikonova, Anna S et al. (2016) Musashi-2 (MSI2) supports TGF-? signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A 113:6955-60
Beck, Tim N; Georgopoulos, Rachel; Shagisultanova, Elena I et al. (2016) EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther 15:2486-2497
Beck, Tim N; Golemis, Erica A; Geynisman, Daniel M (2016) Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with S Eur Urol 70:e75-6
Beck, Tim N; Korobeynikov, Vladislav A; Kudinov, Alexander E et al. (2016) Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep 16:657-71
Beck, Tim N; Kaczmar, John; Handorf, Elizabeth et al. (2015) Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 6:18863-74
Beck, Tim N; Chikwem, Adaeze J; Solanki, Nehal R et al. (2014) Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiol Genomics 46:699-724

Showing the most recent 10 out of 11 publications